Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/05/2003CN1126739C Novel substituted tetrahydropyridin derivatives, method for preparing the same and pharmaceutical composition thereof
11/05/2003CN1126737C Novel pyrrole compound, its preparation and pharmaceutical composition containing the same
11/05/2003CN1126566C Luteinizing hormone releasing hormone antagonist and use for medicine preparation for treating prostate hypertrophy and prostate cancer
11/05/2003CN1126564C Application of phospholipid complexes of extracts of civitis vinifera as anti-atherosclerotic agent
11/05/2003CN1126562C Preparation for treating phlebeaurysma and preparing method thereof
11/05/2003CN1126551C Chinese herb medicine for treating coronary heart disease
11/05/2003CN1126548C Use of zine hyaluronate against peptic ulcer
11/05/2003CN1126547C Lentinan holosida freeze-dried powder injecta and its preparation
11/05/2003CN1126546C Reduction of infarction region using citicoline
11/05/2003CN1126545C Ophthalmic preparations
11/05/2003CN1126544C Shuangmidamo suppository and its preparing process
11/05/2003CN1126543C Pharmaceutical composition for oral administration of N-piperidino-3-phrazolecarboxamide derivative, its salts and their solvates
11/05/2003CN1126542C Non-therapeutic method for promoting strong of male animal
11/05/2003CN1126541C Compound amino acid composition
11/05/2003CN1126540C Plaster containing felbinac
11/05/2003CN1126539C Application of tanshinone in medicine preparation for treating tumor
11/05/2003CN1126538C Carcinostatics
11/05/2003CN1126535C Aqueous suspension for nasal administration of loteprednol
11/05/2003CN1126534C Intracoronary stents fix mould containing quinazolinone derivatives
11/05/2003CN1126533C Improvement of organic composition or improvement related to organic composition
11/04/2003US6642411 Compounds and compositions for delivering active agents
11/04/2003US6642410 Useful as antiproliferative agents, including, for example, anticancer agents
11/04/2003US6642397 Steroid sulphatase inhibitors
11/04/2003US6642391 Amycolatopsis culture product; antibiotic
11/04/2003US6642389 Oxazole derivatives
11/04/2003US6642386 N-(4-carbamimidoyl-phenyl)-glycine derivatives
11/04/2003US6642381 Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
11/04/2003US6642369 Nucleic acids involved in the responder phenotype and applications thereof
11/04/2003US6642368 Programmed cell death and caspase-12
11/04/2003US6642367 Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
11/04/2003US6642365 Anti-(retro)viral conjugates of saccharides and acetamidino or guanidino compounds
11/04/2003US6642363 Bonded to a peptide which promotes cell adhesion and growth; use in drug delivery, cell transplantation and tissue engineering
11/04/2003US6642277 And anthocyanin, cardiovascular disorders, inhibits oxidation of plasma LDL, stimulates TGF production and fibrinolysis and is an anticoagulant
11/04/2003US6642276 Controlled release macrolide pharmaceutical formulations
11/04/2003US6642275 Formulation for respiratory tract administration
11/04/2003US6642274 Methods and compositions for preventing and treating prostate disorders
11/04/2003US6642273 Dermatology, vision defects, cardiovascular disorders, antiinflammatory
11/04/2003US6642272 Method of treating a male impotence condition
11/04/2003US6642271 Potentiating compounds
11/04/2003US6642270 7-substituted fused ring tetracycline compounds
11/04/2003US6642268 Treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.
11/04/2003US6642267 Side effect reduction over opioid analgesics; analgesic and/or anxiolytic action
11/04/2003US6642266 EP4 receptor selective agonists in the treatment of osteoporosis
11/04/2003US6642265 Treating thrombocytopenia, in a mammal, including a human, by administering a hydroxy-1-azobenzene derivative
11/04/2003US6642264 Thiazolobenzoimidazole derivatives
11/04/2003US6642263 Modulators of Rho C activity
11/04/2003US6642262 Therapy for amyotropic lateral sclerosis
11/04/2003US6642261 N-(phenylacetyl)alanine, isobutyl ester for example; prophylaxis and treatment of Alzheimer's disease
11/04/2003US6642260 Nitric oxide donors and pharmaceutical compositions containing them
11/04/2003US6642258 Use of central cannabinoid receptor antagonist for preparing medicines
11/04/2003US6642256 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders
11/04/2003US6642253 Thrombin inhibitors comprising an aminoisoquinoline group
11/04/2003US6642252 Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer.
11/04/2003US6642251 Antitumor, 2-indolinone derivatives
11/04/2003US6642248 Antitumor, anticancer agent
11/04/2003US6642247 Treting anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug
11/04/2003US6642246 Quinuclidine acrylamides
11/04/2003US6642243 Pseudoephedrine, acetaminophen, and caffeine to alleviate the pain and cluster of symptoms characteristic of migraine attacks such as nausea, photophobia, phonophobia,
11/04/2003US6642242 Quinoline and quinazoline compounds useful in therapy
11/04/2003US6642241 Alkylamino- substituted dihydropyrimido-(4,5-d)pyrimidinone derivatives, inhibitors of p38,
11/04/2003US6642240 Treating emesis in a mammal
11/04/2003US6642239 Dipeptide nitrile cathepsin K inhibitors
11/04/2003US6642237 Inhibitors of HIV protease and inhibitors of HIV replication, used in the prevention or treatment of infection by HIV and treatment for AIDS
11/04/2003US6642236 Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
11/04/2003US6642235 Administering a therapeutically effective amount of a formulation comprising compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of 5000; for selectively inhibiting reuptake of norepinephrine
11/04/2003US6642233 Strong affinity and high selectivity for the human NK1 receptors of substance P.
11/04/2003US6642232 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
11/04/2003US6642230 Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
11/04/2003US6642229 3-Phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors
11/04/2003US6642228 α1b-adrenergic receptor antagonists
11/04/2003US6642227 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
11/04/2003US6642226 Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors
11/04/2003US6642225 Diazacycloalkanedione derivatives
11/04/2003US6642224 Activated blood coagulation factor X inhibitors
11/04/2003US6642223 Benzoheterocyclic derivatives
11/04/2003US6642222 Pyrano, piperidino, and thiopyrano compounds and methods of use
11/04/2003US6642221 Vanadium compounds as anti-proliferative agents
11/04/2003US6642219 Treating intermenstrual bleeding in female induced by administration of progestogen-only contraceptive regimen on continuous daily basis, by co-administering, for at least 28 consecutive days, anti-progestogen at specified daily dose
11/04/2003US6642218 (5Z,7E,22E)-(1S,3R,24R)-25-(5-Propyloxazol-2-yl)-26,27-cyclo -9,10-secocholesta-5,7,10(19), 22-tetraene-1,3,24-triol for treatment of diseases characterized by hyperproliferation and deficient cell differentiation
11/04/2003US6642217 Triterpenes having human antifungal and antiyeast activity
11/04/2003US6642216 Osteoporosis, periodontal diseases
11/04/2003US6642214 Oligomer consisting of two cyclodextrin molecules joined by bifunctional spacer, optionally having affinity group which interacts with molecular target structure; physical inclusion complex formed with drug reduces side effects
11/04/2003US6642212 Health supplement comprising naturally occurring phytoestrogen selected from any two or more of genistein, daidzein and/or their glycosides
11/04/2003US6642211 Treatment of cancer with thymidine in combination with temozolamide
11/04/2003US6642210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
11/04/2003US6642209 Administering effective amount of adenosine receptor agonist to human patient to relieve pain selected from post surgical pain and chronic pain
11/04/2003US6642208 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
11/04/2003US6642206 Monocyclic L-nucleosides, analogs and uses thereof
11/04/2003US6642023 High molecular weight; encoded by isolated nucleic acid; expression vectors; use for diagnostics, prophylaxis and treatment of infections
11/04/2003US6642010 Identifying, monitoring, and treating women for breast precancer or cancer
11/04/2003US6642009 Diagnosis of breast cancer by isolating a ductal fluid sample from one duct not mixed with other fluid from other ducts and not being discharged spontaneously; determining the presence/absence of a marker associated with cancer
11/04/2003US6641851 Laxative; solvent extraction of plant; side effect reduction
11/04/2003US6641849 Mixture of L-carnitine, acetyl L-carnitine, and propionyl L-carnitine or salts; cardiovascular, gastrointestinal, sleep, nervous system, and nervous system disorders
11/04/2003US6641847 Cranberry seed oil extract and compositions containing components thereof
11/04/2003US6641843 Pharmaceutical compositions
11/04/2003US6641841 N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and low sustituted hydroxypropylcellulose; controlling the blood sugar levels of diabetics.
11/04/2003US6641840 Sustained release formulations for growth hormone secretagogues
11/04/2003US6641839 Isosorbide mononitrate coated sugar or nonpareil core; time-release agents; diffusion control membrane; prevents nitrate tolerance
11/04/2003US6641835 Method for treating fur or hair pigmentation of domestic carnivores
11/04/2003US6641834 Quinoxaline component is selected from qinoxaline, a (2-imiozoline -2-ylamino) quinoxaline, a 5-bromo-6-(2-imidozolin-2- ylamino) quinoxaline, a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline or derivatives
1 ... 5289 5290 5291 5292 5293 5294 5295 5296 5297 5298 5299 5300 5301 5302 5303 5304 5305 5306 5307 5308 5309 ... 7860